Content area
Full Text
Pharma giant Johnson & Johnson is determined to defend Remicade against a growing biosimilar attack, but now the company has dropped its lawsuit accusing Samsung Bioepis of infringing patents on the blockbuster immunology drug.
Partners Samsung and Merck launched their biosim Renflexis in July, despite the ongoing patent fight. J&J's Janssen unit had sued to block the rollout and asked the court to force Samsung to participate in the "patent dance," a dispute resolution...